BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1674871)

  • 41. Reduced formation of lesions in the DNA of a multidrug-resistant L1210 subline selected for teniposide resistance.
    Roberts DW; Foglesong PD; Parganas E; Wiggins L
    Cancer Chemother Pharmacol; 1989; 23(3):161-8. PubMed ID: 2538249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin.
    Riou JF; Grondard L; Petitgenet O; Abitbol M; Lavelle F
    Biochem Pharmacol; 1993 Sep; 46(5):851-61. PubMed ID: 8396937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sequestration of doxorubicin in vesicles in a multidrug-resistant cell line (LZ-100).
    Sognier MA; Zhang Y; Eberle RL; Sweet KM; Altenberg GA; Belli JA
    Biochem Pharmacol; 1994 Jul; 48(2):391-401. PubMed ID: 7914406
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.
    Cole SP; Chanda ER; Dicke FP; Gerlach JH; Mirski SE
    Cancer Res; 1991 Jul; 51(13):3345-52. PubMed ID: 1675932
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines.
    Coley HM; Amos WB; Twentyman PR; Workman P
    Br J Cancer; 1993 Jun; 67(6):1316-23. PubMed ID: 8099807
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparative study of cellular and molecular pharmacology of doxorubicin and MEN 10755, a disaccharide analogue.
    Bigioni M; Salvatore C; Bullo A; Bellarosa D; Iafrate E; Animati F; Capranico G; Goso C; Maggi CA; Pratesi G; Zunino F; Manzini S
    Biochem Pharmacol; 2001 Jul; 62(1):63-70. PubMed ID: 11377397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
    Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression.
    Nygren P; Larsson R; Gruber A; Peterson C; Bergh J
    Br J Cancer; 1991 Dec; 64(6):1011-8. PubMed ID: 1684906
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanisms regulating cell resistance to adriamycin. Evidence that drug accumulation in resistant cells is modulated by phosphorylation of a plasma membrane glycoprotein.
    Center MS
    Biochem Pharmacol; 1985 May; 34(9):1471-6. PubMed ID: 3994760
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes.
    Thierry AR; Vigé D; Coughlin SS; Belli JA; Dritschilo A; Rahman A
    FASEB J; 1993 Apr; 7(6):572-9. PubMed ID: 8097173
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells.
    Rahman A; Husain SR; Siddiqui J; Verma M; Agresti M; Center M; Safa AR; Glazer RI
    J Natl Cancer Inst; 1992 Dec; 84(24):1909-15. PubMed ID: 1361008
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells.
    Bakic M; Chan D; Freireich EJ; Marton LJ; Zwelling LA
    Cancer Res; 1987 Dec; 47(24 Pt 1):6437-43. PubMed ID: 2824033
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines.
    Kanzawa F; Nishio K; Ishida T; Fukuda M; Kurokawa H; Fukumoto H; Nomoto Y; Fukuoka K; Bojanowski K; Saijo N
    Br J Cancer; 1997; 76(5):571-81. PubMed ID: 9303354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetic transfer of non-P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: dissection of a compound MDR phenotype.
    Eijdems EW; Borst P; Jongsma AP; de Jong S; de Vries EG; van Groenigen M; Versantvoort CH; Nieuwint AW; Baas F
    Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3498-502. PubMed ID: 1348862
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Further characterization of two distinct adriamycin-resistant sublines from LoVo human colon carcinoma cells.
    Yang LY; Trujillo JM; Su YZ
    Anticancer Res; 1992; 12(2):473-9. PubMed ID: 1349796
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protection from adriamycin cytotoxicity in L1210 cells by brefeldin A.
    Vichi PJ; Tritton TR
    Cancer Res; 1993 Nov; 53(21):5237-43. PubMed ID: 8106144
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac.
    Wartlick F; Bopp A; Henninger C; Fritz G
    Biochim Biophys Acta; 2013 Dec; 1833(12):3093-3103. PubMed ID: 23999236
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells.
    Schuurhuis GJ; van Heijningen TH; Cervantes A; Pinedo HM; de Lange JH; Keizer HG; Broxterman HJ; Baak JP; Lankelma J
    Br J Cancer; 1993 Nov; 68(5):898-908. PubMed ID: 8105865
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
    Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA
    Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel cellular determinants for reversal of multidrug resistance in cells expressing P170-glycoprotein.
    Yin MB; Guo B; Voigt W; Vanhoefer U; Gibbs JF; Skenderis BS; Frank C; Wrzosek C; Rustum YM
    Biochim Biophys Acta; 1998 Mar; 1401(3):265-76. PubMed ID: 9540817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.